An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Latest Information Update: 06 Nov 2024
At a glance
- Drugs Temozolomide (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
Most Recent Events
- 04 Nov 2024 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.
- 04 Nov 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
- 28 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.